Dovato (dolutegravir/lamivudine) / ViiV Healthcare - LARVOL DELTA

HIV ENTEROPATHY: CLINICAL, ENDOSCOPIC AND HISTOPATHOLOGICAL FEATURES IN A PATIENT WITH GASTROINTESTINAL ONSET OF HIV INFECTION (UEGW 2025) - "Abdominal ultrasonography revealed invagination of the small intestine and mesenteric lymphadenopathy.After HIV test positivity, a HAART (highly active antiretroviral therapy) with Dolutegravir/Lamivudine was set up...HSV, EBV and CMV tested positive at the immunostaining.Colonoscopy with multiple biopsies showed substantial macroscopic normality, with mild chronic inflammation in every biopsy specimen.Coproparasitological exam, coprocultures and serologic tests for enteropathogenes showed Candida albicans positivity.During the hospitalisation, the patient received antiviral and antifungal therapy, HAART, albumin, fluid therapy, enoxaparin, energy-protein supplements.At follow up, the patient continued HAART regularly, reaching full viral suppression. Weight gain was achieved, with no more episodes of diarrhea. Blood tests showed no more signs of malabsorption."

Clinical • Anemia • Cachexia • Candidiasis • Cardiovascular • Celiac Disease • Gastrointestinal Disorder • Hematological Disorders • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Thrombosis

Switch to Dolutegravir Plus Lamivudine Dual-Therapy in Transgender Women Living With HIV on Virologically Suppressive Antiretroviral Therapy (TRANS-SWITCH) (clinicaltrials.gov) - P4 | N=50 | Recruiting | Sponsor: UBATEC | Not yet recruiting ➔ Recruiting

Enrollment open • Human Immunodeficiency Virus • Infectious Disease

Virological non-inferiority and lower weight gain with DTG/3TC versus BIC/FTC/TAF: 96-week final results from the PASO-DOBLE (GeSIDA 11720) randomised, multicentre, open-label, non-inferiority trial (EACS 2025) - No abstract available

Clinical • Head-to-Head • Late-breaking abstract • Infectious Disease

Multicenter Real-World Study on the Effectiveness of Dolutegravir Plus Lamivudine in Treatment-Naïve People Living with HIV with Baseline Plasma HIV-1 RNA >500,000 Copies/mL (EACS 2025) - No abstract available

Clinical • Late-breaking abstract • Real-world • Real-world evidence • Human Immunodeficiency Virus • Infectious Disease

48-WEEK RESULTS OF SWITCHING FROM DTG/3TC TO BIC/FTC/TAF IN PWH AND NEUROPSYCHIATRIC COMORBIDITIES (EACS 2025) - No abstract available

Infectious Disease

Changes in cardiovascular and metabolic risk scores after switching to DOR/3TC/TDF, DTG/3TC or BIC/FTC/TAF: results from a multicenter Italian cohort (EACS 2025) - No abstract available

Clinical • Infectious Disease

Switching to dolutegravir/lamivudine is non-inferior to continuing triple-drug ART in virologically suppressed people with HIV: 2 year results of the DUALING prospective matched nationwide clinical practice study (EACS 2025) - No abstract available

Clinical • Human Immunodeficiency Virus • Infectious Disease

“Leaving no stones unturned”: 10 years results on the tolerability and metabolic safety of DTG+3TC as a switch regimen (EACS 2025) - No abstract available

Clinical • Infectious Disease

MeP19 - Beyond with DTG/3TC (EACS 2025) - "ePoster Station 3"

Infectious Disease

Evolution of Proviral DNA M184V/I Over 96 Weeks Does Not Predict Virologic Failure of Dolutegravir/Lamivudine in the VOLVER Trial (EACS 2025) - No abstract available

Infectious Disease

The Power of Choice: Perspectives From Healthcare Providers on Early Switch to CAB+RPV LA After Rapid Suppression With DTG/3TC (EACS 2025) - No abstract available

Infectious Disease

Cost-Effectiveness of DTG/3TC Single-Pill Versus Generic ABC/3TC Plus Dolutegravir in Japan: A Markov Model Analysis (EACS 2025) - No abstract available

Cost effectiveness • HEOR • Infectious Disease

Selection of antiretroviral resistance in treatment-experienced PWH with virological failure while on B/F/TAF, DTG/3TC or CAB/RPV LA: Virostar 2.0 study (EACS 2025) - No abstract available

Infectious Disease

Subgroup Analysis of Dolutegravir/Lamivudine-in ART-Naïve Adults Living with HIV with CD4 counts below 200 cells/mL: Results from the DOLCE Study (EACS 2025) - No abstract available

Clinical • Human Immunodeficiency Virus • Infectious Disease • CD4

Impact of switching from a bictegravir- or dolutegravir-based regimen with emtricitabine/tenofovir alafenamide to dolutegravir/lamivudine on weight and metabolic profiles: a randomized, open-label, multicenter, parallel-group trial (EACS 2025) - No abstract available

Clinical • Infectious Disease

The European REGAL Cohort: A Retrospective Real-world Study of the Effectiveness and Tolerability of the Antiretroviral Treatment Regimens DTG/3TC Compared to BIC/FTC/TAF in Older Persons Living with HIV (EACS 2025) - No abstract available

Real-world • Real-world evidence • Retrospective data • Human Immunodeficiency Virus • Infectious Disease

Ten-year results on the effectiveness of DTG+3TC as a switch regimen in the ODOACRE cohort (EACS 2025) - No abstract available

Infectious Disease

Real-world Effectiveness of DTG+3TC in PLHIV With Previous ART Experience but no Genotype Testing: The “AReTi” Study Results (EACS 2025) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Infectious Disease

PAtIent Reported Experiences and perceiveD benefit of treatment with dolutegravir/lamivudine in Europe (PAIRED Europe): Primary Analysis (EACS 2025) - No abstract available

Clinical • Infectious Disease

LONG-TERM BIC/TAF/FTC DURABILITY AND IMPACT OF DTG/3TC OR LONG-ACTING CABO/RPV (EACS 2025) - No abstract available

Infectious Disease

Impact of bictegravir/emtricitabin/tenofovir alafenamid (BIC/TAF/FTC) and Dolutegravir/Lamivudine on Depression Symptoms in People Living with HIV: A Retrospective Analysis of Beck Depression Inventory Scores (EACS 2025) - No abstract available

Retrospective data • Human Immunodeficiency Virus • Infectious Disease

DTG/3TC AS INITIAL THERAPY IN PEOPLE LIVING WITH HIV AND VIRAL LOAD >500,000 COPIES/ML AND CD4 CELL COUNT ≥200/mm3 (EACS 2025) - No abstract available

Human Immunodeficiency Virus • Infectious Disease • CD4

DOLAM-500: 48 and 96-Week Real-World Efficacy and Safety of Dolutegravir Plus Lamivudine in ART-Naïve Individuals with Baseline HIV-1 RNA ≥500,000 copies/mL (EACS 2025) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Human Immunodeficiency Virus • Infectious Disease

Comparative Dynamics of Inflammatory Biomarkers in Antiretroviral-Naïve MSM with HIV initiating DTG/3TC versus BIC/FTC/TAF (EACS 2025) - No abstract available

Biomarker • Human Immunodeficiency Virus • Infectious Disease

CARAVEL: evaluation of real-world antiviral effectiveness and sustainability of the 2-drug regimen Dolutegravir/Lamivudine fixed dose combination in treatment-naïve adults and pre-treated adults who are virologically suppressed, in routine clinical care, in France (EACS 2025) - No abstract available

Clinical • Real-world • Real-world evidence • Infectious Disease